Bioreliance corp:1108045 [14-058358]
Ended Awarded
- Contract number
- HHSN26100006
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77 Part of Sigma-Aldrich Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,474
Award facts
- Contract value 100% obligated
- $3,474.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
About this award
BioReliance Corporation, a Life Sciences Services division of Sigma-Aldrich Corporation, received a Blanket Purchase Agreement (BPA) call award from the National Cancer Institute valued at $3,474 on August 14, 2014, with a completion date of April 30, 2015. The contract, which was not set aside for any specific business category, operates on a firm fixed-price basis and is to be performed at the contractor's facility in Bethesda, Maryland. BioReliance specializes in critical laboratory and testing services, including endotoxin testing, sterility testing, and Limulus Amebocyte Lysate (LAL) testing, which are essential for pharmaceutical product safety and regulatory compliance.
As a subsidiary of Sigma-Aldrich Corporation and an established service provider to federal health research institutions, BioReliance has demonstrated extensive experience supporting the National Institutes of Health and related agencies in drug development and investigational new drug application processes. This award represents a continuation of the company's role as a key testing and microbiological examination provider within the federal biomedical research ecosystem, supporting the National Cancer Institute's research initiatives with specialized scientific capabilities that advance pharmaceutical and biotechnology research at the agency level.
Quick answers
Who was awarded contract HHSN26100006?
HHSN26100006 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on August 14, 2014.
How much is contract HHSN26100006 worth?
The government has obligated $3,474 on HHSN26100006.
Is contract HHSN26100006 an order under another contract?
Yes. HHSN26100006 is a BPA call under HHSN263199800048997B, a blanket purchase agreement.
Was contract HHSN26100006 competed?
The extent of competition for HHSN26100006 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award